Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Becton Dickinson (BDX) Earnings Surpass Estimates in Q2

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise

Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.

Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up

Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.

NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up

NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.

Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates

Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.

Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1

Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.

LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop

LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.

Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.

Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.

Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up

Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.

AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss

AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.

Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat

Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.

PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.

Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up

Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.

Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up

Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.

IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up

IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.

CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up

CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical

The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical

QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat

Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.